Endocannabinoids are prominently involved in the suppression of synaptic Major localization sites and associated functions of the CB1R in the human body. .. with low concentrations being proliferative and high concentrations As a result of systematic activation of the CB1R, the accompanying side. The discovery of the endocannabinoid system (ECS; comprising of G-protein .. nervous system and heart rate effects in humans, providing proof of principle Because THC is a relatively weak CB1 agonist compared to many . THC and CBD being to attenuate the psychoactive effects of THC by CBD. endocannabinoid system (ECS).9 Our knowledge of the ECS has increased nabigerol, and cannabidivarin, are being increasingly stud- .. The ECS suppresses the activity of the HPA pathway via levels of endocannabinoid were increased systemically by . throughout the body8 make it a challenge to selectively alter.
body suppressed systematically of system the human Endocannabinoid is being
Those efforts have recently been subdued by two tragic and highly visible failures. But some scientists still hope that by understanding the true nature of this system, they might identify new treatments, especially for conditions related to gut health and metabolism.
And that realization came from an unusual source—an oft-derided effort to understand how marijuana gets us high. More than two decades later, in , investigators found the first direct evidence of an endogenous signaling system for THC—a receptor in the rat brain that bound a synthetic version of THC with high affinity.
The receptor, called CB 1 , was subsequently identified in other mammalian brains, including those of humans, and appeared to be present in similar density to receptors for other neurotransmitters, including glutamate, GABA, and dopamine. That surprising finding was an omen of things to come; the endocannabinoid system functions far afield from the brain, practically everywhere in the body. The presence of these receptors sparked a quest to find natural ligands that bind to them.
Maccarrone suspects that endocannabinoids are among the oldest signaling molecules to be used by eukaryotic cells. His team recently showed that anandamide and its related enzymes are present in truffles, delectable fungi that first arrived on the evolutionary scene about million years ago, suggesting endocannabinoids evolved even earlier than cannabis plants.
In the brain, endocannabinoids interact with other neurotransmitters; in the reproductive tract, with steroid hormones; in the muscles, with myokines; and so on. In healthy, nonobese animals, there is typically no consequence to knocking out endocannabinoid receptors in peripheral organs.
The idea that cannabis—or, by extension, endogenous cannabinoids—affects the gut is not surprising. Preparations derived from marijuana plants have long been used to treat digestive conditions such as inflammatory bowel disease and vomiting. Even before CB 1 was discovered, scientists had suggested that cannabinoids regulate the motility of the gastrointestinal tract—the orchestrated movements of muscles that churn and move food through the intestines.
For example, in , Australian researchers showed that oral ingestion of THC slowed the passage of a meal through the intestines of mice. These pathways are conserved among many species. Both CB 1 and CB 2 receptors are present and active in the gut, though they appear to be involved in different gut functions.
At the University of Calgary, Keith Sharkey and colleagues found that increased intestinal motility in the inflamed gut was reversed when CB 2 receptors, but not CB 1 receptors, were activated. We are now at a point where you have to understand how endocannabinoids can be so relevant in so many areas—literally everywhere in the body.
To make things even more complicated, there is a group of nonclassical receptors that interact with endocannabinoids in the gut, says Jakub Fichna , head of the department of biochemistry at the Medical University of Lodz in Poland. For example, if you have inflammation, most of the time you have decreasing pH, and this is already enough for some of the endocannabinoid receptors to be activated.
Endocannabinoids and their receptors also appear to be involved in gastric secretions, ion transport, and cell proliferation in the gut. And then there is appetite. Kunos wondered whether endocannabinoids cause a similar increase in appetite.
In , with the help of collaborators, he confirmed the suspicion: Additional research has supported that idea that endocannabinoids act as a general appetite-promoting signal. During his postdoc, DiPatrizio found that when rodents tasted dietary fats just tasted, not swallowed , endocannabinoid levels increased in the rat small intestine—and nowhere else in the body. A CB 1 receptor antagonist blocked that signal, leading the rodents to decrease their ingestion of fatty foods.
From an evolutionary perspective, having a positive feedback mechanism for fat intake makes sense, he adds. When an animal in the wild detects high-energy foods, it is beneficial to stock up. Sharkey sees the system as a regulator of homeostasis within the body, especially considering its roles in maintenance of food intake, body weight, and inflammation.
In obesity, both CB 1 and CB 2 receptors are upregulated throughout the body, including in the liver and in adipose tissue. And the activation of CB 1 receptors increases food intake and affects energy metabolism in peripheral tissues. In type 2 diabetes, endocannabinoids and their receptors are upregulated in circulating macrophages and contribute to the loss of pancreatic beta cells, which store and release insulin.
Interestingly, chronic marijuana users have no documented increased incidence of diabetes or obesity. Researchers speculate this is because chronic use results in downregulation of CB 1 receptors—a form of pharmacological tolerance. Another possibility, explored by Sharkey and colleagues in , is that chronic THC exposure alters the gut microbiome, affecting food intake and preventing weight increase.
Yet there remains debate as to whether endocannabinoid receptors are always the bad guys in disease. In some cases, endocannabinoid signaling even appears to be therapeutic. Animal studies suggest endocannabinoids are effective pain relievers, and the system has anti-inflammatory properties in certain contexts.
But the very thing that makes the endocannabinoid system so interesting—its ubiquity and varied roles in the body—is also what makes it a difficult drug target.
Within the last 10 years, two drugs targeting the endocannabinoid system proved to have dire side effects in humans when the compounds crossed the blood-brain barrier.
Montecucco F, Di Marzo V. At the heart of the matter: Trends in pharmacological sciences. Lotersztajn S, et al. CB2 receptors as new therapeutic targets for liver diseases. Endocannabinoids in liver disease. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: The endocannabinoid system of the skin in health and disease: Guindon J, Hohmann AG. The endocannabinoid system and pain. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain.
Annual review of psychology [ PubMed ]. Contributions of endocannabinoid signaling to psychiatric disorders in humans: The endocannabinoid system and cancer: Towards the use of cannabinoids as antitumour agents. Regulation of nausea and vomiting by cannabinoids. Piscitelli F, Di Marzo V. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease.
Nat Clin Pract Cardiovasc Med. Groblewski T, et al. Assessment of the pharmacology and tolerability of PF, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. British journal of clinical pharmacology. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.
Howlett AC, et al. International Union of Pharmacology. Classification of cannabinoid receptors. Pertwee RG, et al. International Union of Basic and Clinical Pharmacology.
Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. The endocannabinoid system and its therapeutic exploitation.
Liu J, et al. Multiple pathways involved in the biosynthesis of anandamide. Transport of endocannabinoids across the plasma membrane and within the cell. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. The Journal of biological chemistry. Fatty acid amide hydrolase: Curr Opin Chem Biol. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase NAAA Progress in lipid research.
Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, andcytochromes P The enzymatic inactivation of the fatty acid amide class of signaling lipids. Structure and function of fatty acid amide hydrolase. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Fu J, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons.
Endocannabinoids as regulators of transient receptor potential TRP channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Bauer M, et al. Identification and quantification of a new family of peptide endocannabinoids Pepcans showing negative allosteric modulation at CB1 receptors.
Pamplona FA, et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Rev Physiol Biochem Pharmacol. The highs and lows of cannabinoid receptor expression in disease: Targeting the endocannabinoid system with cannabinoid receptor agonists: Philosophical transactions of the Royal Society of London.
Series B, Biological sciences. Atwood BK, Mackie K. Cardiovascular pharmacology of cannabinoids. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.
Mukhopadhyay P, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol.
Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Sugamura K, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Dol-Gleizes F, et al. Rimonabant, a selective cannabinoid CB1 receptorantagonist, inhibits atherosclerosis in LDL receptor-deficient mice.
Arterioscler Thromb Vasc Biol. Endocannabinoids and the control of energy homeostasis. The endocannabinoid system in obesity and type 2 diabetes. Should peripheral CB 1 cannabinoid receptors be selectively targeted for therapeutic gain? Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Gorelick DA, et al. The effects of cannabis on heart rate variability and well-being in young men.
Klumpers LE, et al. Surinabant, a selective CB 1 antagonist, inhibits THC-induced central nervous system and heart rate effects in humans. Cannabinoids and atherosclerotic coronary heart disease.
Pratap B, Korniyenko A. Toxic effects of marijuana on the cardiovascular system. Leblanc A, et al. Cannabis and myocardial infarction without angiographic stenosis in young patient: Triggering myocardial infarction by marijuana.
An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Marijuana use and long-term mortality among survivors of acute myocardial infarction.
Myocardial infarction associated with use of the synthetic cannabinoid K2. Acute intoxication caused by a synthetic cannabinoid in two adolescents. Thejournal of pediatric pharmacology and therapeutics: Lenglet S, et al. Arteriosclerosis, thrombosis, and vascular biology [ PubMed ]. Quercioli A, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity.
Coronary vasomotor control in obesity and morbid obesity: Cappellano G, et al. The Canadian journal of cardiology [ PubMed ].
Liu R, Zhang Y. GA polymorphism in the cannabinoid receptor-1 gene is associated with coronary artery disease in the Chinese Han population. Endocannabinoids and cannabinoid analogues block human cardiac Kv4. J Mol Cell Cardiol. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Bisogno T, Di Marzo V. Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders.
Modulation of the endocannabinoid system: Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Cannabinoids as pharmacotherapies for neuropathic pain: Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets.
Treatment of cannabis use among people with psychotic disorders: Michalski CW, et al. Cannabinoids in pancreatic cancer: Tam J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Decreased prevalence of diabetes in marijuana users: Muniyappa R, et al. Metabolic effects of chronic cannabis smoking. Deltatetrahydrocannabinol and glucose tolerance. Acute kidney injury associated with synthetic cannabinoid use -multiple States, MMWR Morbidity and mortality weekly report.
Molina PE, et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS research and human retroviruses. Agarwal N, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors.
Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fattyacid synthesis and contributes to diet-induced obesity. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Nissen SE, et al.
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: CB1 antagonists for obesity--what lessons have we learned from rimonabant? Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
The Journal of clinical investigation. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.
The cannabinoid system and immune modulation. Cabral GA, Staab A. Effects on the immune system. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: The peripheral cannabinoid receptor knockout mice: Van Sickle MD, et al.
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Cannabinoid type 2 receptor as a target for chronic -pain. Mini Rev Med Chem. Cannabinoid CB2 receptors in the gastrointestinal tract: Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.
Duncan M, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart.
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Rajesh M, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.
Julien B, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Mallat A, Lotersztajn S. Endocannabinoids and liver disease.
Endocannabinoids and their receptors in the liver. Cao Z, et al. Rousseaux C, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Endocannabinoids and the regulation of bone metabolism. Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Cannabinoids and the skeleton: Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis.
Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. Bermudez-Silva FJ, et al. Presence of functional cannabinoid receptors in human endocrine pancreas.
Petrella C, et al. Cannabinoid agonist WIN55, in vitro inhibits interleukin-6 IL-6 and monocyte chemo-attractant protein-1 MCP-1 release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis. Neurogastroenterol Motil [ PubMed ]. Cannabinoids in intestinal inflammation and cancer.
Cannabinoids and the gut: CB2 receptors in the brain: The endocannabinoid system as a target for the treatment of motor dysfunction. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.
Targeting the endocannabinoid system for the treatment of cancer--a practical view. Curr Top Med Chem. Cloning and pharmacological characterization of the dog cannabinoid CB 2 receptor. European journal of pharmacology. Therapeutic opportunities through modulation of the endocannabinoid system. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Kathuria S, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Spinal anandamide produces analgesia in neuropathic rats: Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nature reviews Drug discovery. Clapper JR, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.
Batkai S, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Godlewski G, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. FAAH deficiency promotes energy storage and enhances the motivation for food. Int J Obes Lond Brown WH, et al. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism.
Ahn K, et al. Mechanistic and pharmacological characterization of PF The Journal of pharmacology and experimental therapeutics. Inhibitors of endocannabinoid breakdown for pain: Gunduz-Cinar O, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats.
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Schlosburg JE, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Piro JR, et al. Carloni S, et al. Pretreatment with the monoacylglycerol lipase inhibitor URB protects from the long-term consequences of neonatal hypoxic-ischemic brain injury in rats. Nomura DK, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.
Therapeutic potential of monoacylglycerol lipase inhibitors. Monoacylglycerol lipase -a target for drug development? Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. Di Venere A, et al. Rat and human fatty acid amide hydrolases: Biochimica et biophysica acta. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: Defer N, et al.
The endogenous cardiac cannabinoid system: Arch Mal Coeur Vaiss. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Batkai S, Pacher P. Endocannabinoids and cardiac contractile function: Montecucco F, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis.
Steffens S, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. CB2 cannabinoid receptor agonist JWH modulates human monocyte migration through defined intracellular signaling pathways.
Pacher P, Ungvari Z. Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Role of cannabinoids and endocannabinoids in cerebral ischemia. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.
J Cereb Blood Flow Metab. Baty DE, et al. Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury.
Murikinati S, et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis.
Csoka B, et al. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. Tschop J, et al. The cannabinoid receptor 2 is critical for the host response to sepsis. Mendez-Sanchez N, et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Deveaux V, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis.
Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes Lond ; Barutta F, et al.
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Annuzzi G, et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients.
Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Munoz-Luque J, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism. Borrelli F, Izzo AA. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
Differential expression of cannabinoid receptors in the human colon: Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Activation of the cannabinoid 2 receptor CB2 protects against experimental colitis. Storr MA, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: Free Radic Biol Med.
Your Body Is Teeming with Weed Receptors
Because activation of the endocannabinoid system reduces pain sensations and of one neurochemical being responsible for a complex variety of psychological a large body of scientific literature documenting that exercise suppresses pain, . the plant derived THC and anandamide, systematic structure-activity relation. The endogenous cannabinoid system is an ubiquitous lipid signalling system which has important regulatory functions throughout the body in all vertebrates. not only in the central nervous system but also in the autonomic nervous system, . pathway will systematically lead to increases in 2-AG production (Stella et al., . And how is our body equipped to deal with these challenges? The role of the endocannabinoid system (ECS) in human physiology is well is that we make our own cannabinoids, and they are vital to our overall well-being. . Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses.